Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 9/2015

01-09-2015 | Article

Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran

Authors: M. T. Hedayati, Y. Azimi, A. Droudinia, B. Mousavi, A. Khalilian, N. Hedayati, D. W. Denning

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2015

Login to get access

Abstract

In patients with preexisting lung disease, especially a cavity, Aspergillus can infect the surface of the cavity, causing chronic cavitary pulmonary aspergillosis (CCPA), and may form an aspergilloma, collectively called chronic pulmonary aspergillosis (CPA). In the present study, we assessed tuberculosis (TB) patients for CPA based on culture and serological methods. During a period of 1 year (from March 2013 to March 2014), we studied 124 patients with TB (94 with current TB and 30 with previous TB) at Masih Daneshvari Hospital in Tehran, Iran. Sputum specimens were analyzed by direct microscopic examination (DME) and fungal culture. The clinical and radiological features of all patients were recorded, to categorize the patients into CCPA and aspergilloma. All patients were screened for serum-specific IgG against A. fumigatus, by enzyme-linked immunosorbent assay (ELISA). Out of 124 patients with TB (66 male, age range: 10–91 years), 48 patients (38.7 %) exhibited residual cavities. Eighteen (14.5 %) patients had cavities with pleural thickening. A round-shaped mass lesion was detected in six patients (6.8 %). DME was positive in ten patients for septate fungal hyphae. A. fumigatus was grown from 14 samples. Fifty-five (44.3 %) cases were positive for serum-specific IgG against A. fumigatus. Of 124 patients with TB, 3 (2.4 %) met criteria for aspergilloma and 14 (11.3 %) for CCPA. CPA is a common clinical presentation in individuals with healed TB in Iran, as reported by previous studies from other countries.
Literature
1.
go back to reference Murray CJ, Ortblad KF, Guinovart C et al (2014) Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9947):1005–1070PubMedCentralCrossRefPubMed Murray CJ, Ortblad KF, Guinovart C et al (2014) Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9947):1005–1070PubMedCentralCrossRefPubMed
2.
go back to reference Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, Dubaniewicz A, Singh M, Myśliwski A (2006) Comparative analysis of mycobacterial heat shock proteins-induced apoptosis of peripheral blood mononuclear cells in sarcoidosis and tuberculosis. J Clin Immunol 26(3):243–250CrossRefPubMed Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, Dubaniewicz A, Singh M, Myśliwski A (2006) Comparative analysis of mycobacterial heat shock proteins-induced apoptosis of peripheral blood mononuclear cells in sarcoidosis and tuberculosis. J Clin Immunol 26(3):243–250CrossRefPubMed
3.
go back to reference Yan L, Cui H, Xiao H, Zhang Q (2013) Anergic pulmonary tuberculosis is associated with contraction of the Vd2+T cell population, apoptosis and enhanced inhibitory cytokine production. PLoS One 8(8):e71245PubMedCentralCrossRefPubMed Yan L, Cui H, Xiao H, Zhang Q (2013) Anergic pulmonary tuberculosis is associated with contraction of the Vd2+T cell population, apoptosis and enhanced inhibitory cytokine production. PLoS One 8(8):e71245PubMedCentralCrossRefPubMed
5.
go back to reference Denning DW, Riniotis K, Dobrashian R, Sambatakou H (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37(Suppl 3):S265–S280CrossRefPubMed Denning DW, Riniotis K, Dobrashian R, Sambatakou H (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37(Suppl 3):S265–S280CrossRefPubMed
6.
go back to reference Camuset J, Nunes H, Dombret MC et al (2007) Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 131:1435–1441CrossRefPubMed Camuset J, Nunes H, Dombret MC et al (2007) Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 131:1435–1441CrossRefPubMed
7.
go back to reference Addrizzo-Harris DJ, Harkin TJ, McGuinness G, Naidich DP, Rom WN (1997) Pulmonary aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest 111:612–618CrossRefPubMed Addrizzo-Harris DJ, Harkin TJ, McGuinness G, Naidich DP, Rom WN (1997) Pulmonary aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest 111:612–618CrossRefPubMed
8.
go back to reference Smith NL, Denning DW (2011) Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37(4):865–872CrossRefPubMed Smith NL, Denning DW (2011) Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37(4):865–872CrossRefPubMed
9.
go back to reference Kosmidis C, Denning DW (2015) The clinical spectrum of pulmonary aspergillosis. Thorax 70(3):270–277CrossRefPubMed Kosmidis C, Denning DW (2015) The clinical spectrum of pulmonary aspergillosis. Thorax 70(3):270–277CrossRefPubMed
11.
go back to reference Kurhade AM, Deshmukh JM, Fule RP, Chande C, Akulwar S (2002) Mycological and serological study of pulmonary aspergillosis in central India. Indian J Med Microbiol 20(3):141–144PubMed Kurhade AM, Deshmukh JM, Fule RP, Chande C, Akulwar S (2002) Mycological and serological study of pulmonary aspergillosis in central India. Indian J Med Microbiol 20(3):141–144PubMed
12.
go back to reference Shahid M, Malik A, Bhargava R (2001) Prevalence of Aspergillosis in chronic lung diseases. Indian J Med Microbiol 19(4):201–205PubMed Shahid M, Malik A, Bhargava R (2001) Prevalence of Aspergillosis in chronic lung diseases. Indian J Med Microbiol 19(4):201–205PubMed
13.
go back to reference Sakarya ME, Özbay B, Yalcinkaya I, Arsalan H, Uzun K, Poykaz N (1998) Aspergillomas in the lung cavities. East J Med 3(1):7–9 Sakarya ME, Özbay B, Yalcinkaya I, Arsalan H, Uzun K, Poykaz N (1998) Aspergillomas in the lung cavities. East J Med 3(1):7–9
14.
go back to reference Ferreira-Da-Cruz MF, Wanke B, Pirmez C, Galvão-Castro B (1988) Aspergillus fumigatus fungus ball in hospitalized patients with chronic pulmonary disease. Usefulness of double immunodiffusion test as a screening procedure. Mem Inst Oswaldo Cruz 83:357–360CrossRefPubMed Ferreira-Da-Cruz MF, Wanke B, Pirmez C, Galvão-Castro B (1988) Aspergillus fumigatus fungus ball in hospitalized patients with chronic pulmonary disease. Usefulness of double immunodiffusion test as a screening procedure. Mem Inst Oswaldo Cruz 83:357–360CrossRefPubMed
15.
go back to reference Iwata H, Miwa T, Takagi K (1990) Tuberculosis sequelae: secondary fungal infections. Kekkaku 65:867–871PubMed Iwata H, Miwa T, Takagi K (1990) Tuberculosis sequelae: secondary fungal infections. Kekkaku 65:867–871PubMed
16.
go back to reference Raper KB, Fennell DI (1973) The genus Aspergillus. Robert E. Krieger Publishing Company, New York Raper KB, Fennell DI (1973) The genus Aspergillus. Robert E. Krieger Publishing Company, New York
17.
go back to reference Hope WW, Walsh TJ, Denning DW (2005) The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 43:S207–S238CrossRefPubMed Hope WW, Walsh TJ, Denning DW (2005) The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 43:S207–S238CrossRefPubMed
18.
go back to reference Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB (1997) Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 112:541–548CrossRefPubMed Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB (1997) Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 112:541–548CrossRefPubMed
19.
go back to reference Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW (2013) Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis 57(6):828–835PubMedCentralCrossRefPubMed Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW (2013) Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis 57(6):828–835PubMedCentralCrossRefPubMed
20.
go back to reference Biswas D, Agarwal S, Sindhwani G, Rawat J (2010) Fungal colonization in patients with chronic respiratory diseases from Himalayan region of India. Ann Clin Microbiol Antimicrob 9:28–35PubMedCentralCrossRefPubMed Biswas D, Agarwal S, Sindhwani G, Rawat J (2010) Fungal colonization in patients with chronic respiratory diseases from Himalayan region of India. Ann Clin Microbiol Antimicrob 9:28–35PubMedCentralCrossRefPubMed
21.
go back to reference Sivasankari S, Senthamarai S, Anitha C et al (2014) Prevalence of invasive aspergillosis among (PTB) patients in Kanchipuram, India. J Clin Diagn Res 8(3):22–23 Sivasankari S, Senthamarai S, Anitha C et al (2014) Prevalence of invasive aspergillosis among (PTB) patients in Kanchipuram, India. J Clin Diagn Res 8(3):22–23
22.
go back to reference Shirai M, Hayakawa H, Uchiyama H, Chida K, Nakamura H (2001) Clinical significance of potential pathogenic microorganisms of sputum in patients with pulmonary tuberculosis. Respirology 6(4):311–315CrossRefPubMed Shirai M, Hayakawa H, Uchiyama H, Chida K, Nakamura H (2001) Clinical significance of potential pathogenic microorganisms of sputum in patients with pulmonary tuberculosis. Respirology 6(4):311–315CrossRefPubMed
23.
go back to reference Salek Moghaddam A, Soltani Arabshahi SK, Yasami A, Tabatabaie S (2001) Survey of humoral immunity against Aspergillus fumigatus in patients with TB and COPD referred to Iran university hospitals. Pejouhesh 25(3):143–147 Salek Moghaddam A, Soltani Arabshahi SK, Yasami A, Tabatabaie S (2001) Survey of humoral immunity against Aspergillus fumigatus in patients with TB and COPD referred to Iran university hospitals. Pejouhesh 25(3):143–147
24.
go back to reference Nakamoto K, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y (2013) Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med 52(7):727–734CrossRefPubMed Nakamoto K, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y (2013) Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med 52(7):727–734CrossRefPubMed
25.
go back to reference Ohba H, Miwa S, Shirai M et al (2012) Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 106(5):724–729CrossRefPubMed Ohba H, Miwa S, Shirai M et al (2012) Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 106(5):724–729CrossRefPubMed
26.
go back to reference Uffredi ML, Mangiapan G, Cadranel J, Kac G (2003) Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 22(8):457–462CrossRefPubMed Uffredi ML, Mangiapan G, Cadranel J, Kac G (2003) Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 22(8):457–462CrossRefPubMed
27.
go back to reference Kitasato Y, Tao Y, Hoshino T et al (2009) Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology 14(5):701–708CrossRefPubMed Kitasato Y, Tao Y, Hoshino T et al (2009) Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology 14(5):701–708CrossRefPubMed
28.
go back to reference Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, Richardson MD (2014) Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR. Mycoses 57:69–78CrossRefPubMed Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, Richardson MD (2014) Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR. Mycoses 57:69–78CrossRefPubMed
29.
go back to reference Jin E, Wang LM, Li QY, Feng X, Ma SL (2014) Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient: report of a rare case. Infection 42(3):565–568CrossRefPubMed Jin E, Wang LM, Li QY, Feng X, Ma SL (2014) Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient: report of a rare case. Infection 42(3):565–568CrossRefPubMed
30.
go back to reference Tashiro T, Izumikawa K, Tashiro M et al (2013) A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn J Infect Dis 66(4):312–316CrossRefPubMed Tashiro T, Izumikawa K, Tashiro M et al (2013) A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn J Infect Dis 66(4):312–316CrossRefPubMed
31.
go back to reference Pendleton M, Denning DW (2012) Multifocal pulmonary aspergillomas: case series and review. Ann N Y Acad Sci 1272:58–67CrossRefPubMed Pendleton M, Denning DW (2012) Multifocal pulmonary aspergillomas: case series and review. Ann N Y Acad Sci 1272:58–67CrossRefPubMed
32.
go back to reference Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89:864–872PubMedCentralCrossRefPubMed Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89:864–872PubMedCentralCrossRefPubMed
33.
go back to reference [No authors listed] (1968) Aspergillus in persistent lung cavities after tuberculosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 49:1–11CrossRef [No authors listed] (1968) Aspergillus in persistent lung cavities after tuberculosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 49:1–11CrossRef
34.
go back to reference [No authors listed] (1970) Aspergilloma and residual tuberculous cavities—the results of a resurvey. Tubercle 51:227–245CrossRef [No authors listed] (1970) Aspergilloma and residual tuberculous cavities—the results of a resurvey. Tubercle 51:227–245CrossRef
35.
go back to reference Pena TA, Soubani AO, Samavati L (2011) Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 189(2):167–172CrossRefPubMed Pena TA, Soubani AO, Samavati L (2011) Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 189(2):167–172CrossRefPubMed
36.
go back to reference Schweer KE, Bangard C, Hekmat K, Cornely OA (2014) Chronic pulmonary aspergillosis. Mycoses 57(5):257–270CrossRefPubMed Schweer KE, Bangard C, Hekmat K, Cornely OA (2014) Chronic pulmonary aspergillosis. Mycoses 57(5):257–270CrossRefPubMed
37.
go back to reference Vahid B, Marik P (2007) Fatal massive hemoptysis in a patient on low-dose oral prednisone: chronic necrotizing pulmonary aspergillosis. Respir Care 52:56–58PubMed Vahid B, Marik P (2007) Fatal massive hemoptysis in a patient on low-dose oral prednisone: chronic necrotizing pulmonary aspergillosis. Respir Care 52:56–58PubMed
38.
go back to reference Kokkonouzis I, Athanasopoulos I, Doulgerakis N et al (2011) Fatal hemoptysis due to chronic cavitary pulmonary aspergillosis complicated by nontuberculous mycobacterial tuberculosis. Case Rep Infect Dis 2011:837146PubMedCentralPubMed Kokkonouzis I, Athanasopoulos I, Doulgerakis N et al (2011) Fatal hemoptysis due to chronic cavitary pulmonary aspergillosis complicated by nontuberculous mycobacterial tuberculosis. Case Rep Infect Dis 2011:837146PubMedCentralPubMed
39.
go back to reference Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A (2013) Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 56(5):559–570CrossRefPubMed Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A (2013) Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 56(5):559–570CrossRefPubMed
40.
go back to reference Cadranel J, Philippe B, Hennequin C et al (2012) Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 31(11):3231–3239PubMedCentralCrossRefPubMed Cadranel J, Philippe B, Hennequin C et al (2012) Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 31(11):3231–3239PubMedCentralCrossRefPubMed
41.
go back to reference Jain LR, Denning DW (2006) The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 52:e133–e137CrossRefPubMed Jain LR, Denning DW (2006) The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 52:e133–e137CrossRefPubMed
Metadata
Title
Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran
Authors
M. T. Hedayati
Y. Azimi
A. Droudinia
B. Mousavi
A. Khalilian
N. Hedayati
D. W. Denning
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 9/2015
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-015-2409-7

Other articles of this Issue 9/2015

European Journal of Clinical Microbiology & Infectious Diseases 9/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine